Program of the Hungarian Academy of Sciences(LP2015-2/2015)
‘Lendület’ Program of the Hungarian Academy of Sciences(LP2015-2/2015)
European Research Council Starting Grant(715043)
European Research Council(ERC, 715043)
New National Excellence Program of the Ministry for Innovation and Technology(ÚNKP-20-3)
(SPIRITS 2020 of Kyoto University)
NKFIH(KH125294)
NKFIH(K135561)
Studying animal models furthers our understanding of Parkinson’s disease (PD) pathophysiology
by providing tools to investigate detailed molecular, cellular and circuit functions.
Different versions of the neurotoxin-based 6-hydroxydopamine (6-OHDA) model of PD
have been widely used in rats. However, these models typically assess the result of
extensive and definitive dopaminergic lesions that reflect a late stage of PD, leading
to a paucity of studies and a consequential gap of knowledge regarding initial stages,
in which early interventions would be possible. Additionally, the better availability
of genetic tools increasingly shifts the focus of research from rats to mice, but
few mouse PD models are available yet. To address these, we characterize here the
behavioral, neuronal and ultrastructural features of a graded-dose unilateral, single-injection,
striatal 6-OHDA model in mice, focusing on early-stage changes within the first two
weeks of lesion induction. We observed early onset, dose-dependent impairments of
overall locomotion without substantial deterioration of motor coordination. In accordance,
histological evaluation demonstrated a partial, dose-dependent loss of dopaminergic
neurons of substantia nigra pars compacta (SNc). Furthermore, electron microscopic
analysis revealed degenerative ultrastructural changes in SNc dopaminergic neurons.
Our results show that mild ultrastructural and cellular degradation of dopaminergic
neurons of the SNc can lead to certain motor deficits shortly after unilateral striatal
lesions, suggesting that a unilateral dose-dependent intrastriatal 6-OHDA lesion protocol
can serve as a successful model of the early stages of Parkinson’s disease in mice.